Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Boulogne-Billancourt – page 32

3 430 clinical trials in Boulogne-Billancourt, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Boulogne-Billancourt at a glance
3 430
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 430 trials in Boulogne-Billancourt

Open in trial search

A study of DS-3790A, rituximab, and epcoritamab in patients with blood cancers

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:DS-3790A
  • Sponsor:Daiichi Sankyo Inc.

HIV infection

Recruiting

A study of islatravir and ulonivirine for adults with HIV who have not received previous treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Merck Sharp & Dohme LLC

A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults.

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD5148
  • Sponsor:AstraZeneca AB

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tafasitamab
  • Sponsor:Incyte Corp.

A study to evaluate the safety and effectiveness of H-CYS(SS)-GLU-VAL-SER-GLN-LEU-LEU-LYS-GLY-ASP-ALA-CYS(SS)-OH in patients with advanced solid tumors who have completed other treatments.

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:TAX2
  • Sponsor:Apmonia Therapeutics

A study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BNT324
  • Sponsor:BioNTech SE

Canavan disease

Recruiting

A study to evaluate the effectiveness of ciracigene golparvovec in children with Canavan disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ciracigene golparvovec
  • Sponsor:Myrtelle Inc.

Comparing the timing of etoposide and dexamethasone treatment for patients with severe sporadic hemophagocytic lymphohistiocytosis in intensive care.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Etoposide
  • Sponsor:Assistance Publique Hopitaux De Paris

A study to evaluate the long-term safety and effectiveness of mRNA-3927 in patients with Propionic Acidemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Modified Messenger Ribonucleic Acid Encoding Human Propionyl-Coenzyme A Carboxylase Alpha And Beta Subunits Encapsulated Into Lipid Nanoparticles
  • Sponsor:Moderna Inc.

Acute leukaemia

Recruiting

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Enzomenib
  • Sponsor:Sumitomo Pharma America Inc.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Boulogne-Billancourt

What the registry says about research in the country

01 Lung Cancer Research

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) and novel treatment approaches, including immunotherapy combinations and targeted therapies.

  • Advanced stage treatment evaluation
  • Immunotherapy effectiveness
  • Combination therapy assessment

Studies investigating various treatment strategies for both elderly patients and those with specific genetic mutations.

02 Melanoma Studies

Research centered on advanced melanoma treatment, particularly in high-risk stages and post-surgical care.

  • Adjuvant therapy trials
  • Stage III melanoma management
  • Immunotherapy protocols

Focus on improving survival rates through targeted therapeutic approaches and immune system modulation.

03 Kidney and Cardiovascular Research

Investigations into chronic kidney disease (CKD) treatment and cardiac conditions, including innovative therapeutic combinations.

  • Blood pressure management
  • Cardiac function improvement
  • Disease progression prevention

Studies evaluating new treatment approaches for patients with complex cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.